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Droplet digital PCR-based EGFR 
mutation detection with an internal 
quality control index to determine 
the quality of DNA
Sung-Su Kim1,3, Hyun-Jeung Choi2,3, Jin Ju Kim2,3, M. Sun Kim4, In-Seon Lee3, Bohyun Byun3, 
Lina Jia5, Myung Ryurl Oh6, Youngho Moon4, Sarah Park3, Joon-Seok Choi7,  
Seoung Wan Chae8, Byung-Ho Nam9, Jin-Soo Kim10, Jihun Kim  11, Byung Soh Min12,  
Jae Seok Lee13, Jae-Kyung Won14, Soo Youn Cho15, Yoon-La Choi15 & Young Kee Shin1,3,16
In clinical translational research and molecular in vitro diagnostics, a major challenge in the detection of 
genetic mutations is overcoming artefactual results caused by the low-quality of formalin-fixed paraffin-
embedded tissue (FFPET)-derived DNA (FFPET-DNA). Here, we propose the use of an ‘internal quality 
control (iQC) index’ as a criterion for judging the minimum quality of DNA for PCR-based analyses. In a 
pre-clinical study comparing the results from droplet digital PCR-based EGFR mutation test (ddEGFR 
test) and qPCR-based EGFR mutation test (cobas EGFR test), iQC index ≥ 0.5 (iQC copies ≥ 500, using 
3.3 ng of FFPET-DNA [1,000 genome equivalents]) was established, indicating that more than half of 
the input DNA was amplifiable. Using this criterion, we conducted a retrospective comparative clinical 
study of the ddEGFR and cobas EGFR tests for the detection of EGFR mutations in non-small cell lung 
cancer (NSCLC) FFPET-DNA samples. Compared with the cobas EGFR test, the ddEGFR test exhibited 
superior analytical performance and equivalent or higher clinical performance. Furthermore, iQC index 
is a reliable indicator of the quality of FFPET-DNA and could be used to prevent incorrect diagnoses 
arising from low-quality samples.
In light of recent advancements in personalized medicine, nucleic acid-based diagnostics will play a pivotal role in 
implementation of targeted therapies. In non-small cell lung cancer (NSCLC), EGFR exon 19 deletion and L858R 
mutations are predictive biomarkers for EGFR tyrosine kinase inhibitor (TKI) efficacy; both markers are associ-
ated with significantly longer progression-free survival (PFS)1–5. Thus, accurate detection of EGFR mutations is 
critical for individualized treatment strategies for NSCLC.
Formalin-fixed, paraffin-embedded tissue (FFPET) is the most widely available material for molecular diag-
nostics and clinical research6. However, the FFPET fixation procedure and long-term storage at room temperature 
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causes several kinds of damage to nucleic acids, creating challenges to molecular analyses using FFPET-derived 
DNA (FFPET-DNA)7. First, DNA fragmentation, a common form of DNA damage, is associated with longer 
storage periods and the low pH of the formalin used in tissue fixation8. The small size of DNAs produced by 
DNA fragmentation in FFPET affect PCR amplification, and the success rate of PCR is dependent on the size of 
the amplicon9. Second, hydrolytic deamination of cytosine yields uracil lesions, which have been identified as a 
major source of sequence artifacts in FFPET-DNA10,11. Among the sequence artifacts detected in FFPET-DNA, 
C:G > T:A transitions are the most frequent type of single nucleotide variants (SNVs)12. Surprisingly, the EGFR 
T790M mutation, which causes TKI resistance in NSCLC patients, can yield a false-positive result owing to 
cytosine deamination13,14. Third, cross-linked DNA reduces the stability of dsDNA, affecting the amount of 
FFPET-DNA that can be amplified by PCR15. Cross-linking not only causes problems with DNA isolation, but 
also significantly affects PCR amplification16. Fourth, formalin fixation time significantly influences the quality of 
FFPET-DNA and consequently the results of PCR analysis17. Thus, because of the differences in storage duration 
and fixation procedures among laboratories, FFPET-DNA quality should be checked before being used in clinical 
studies.
Droplet digital PCR (ddPCR) is an assay that combines state-of-the-art microfluidics technology with 
TaqMan-based PCR to achieve precise target DNA quantification at high levels of sensitivity and specificity. Due 
to its technological advantages, which confer highly sensitive mutation detection, this method has been adopted 
in clinical research18–22. Notably, DNA integrity can also be assessed using ddPCR technology19. However, the 
clinical performance of ddPCR-based tests with FFPET-DNA quality measurement has not been subjected to a 
detailed comparison with gold standards, such as qPCR.
In this study, we report the development of sample criteria for the minimum FFPET-DNA quality suitable 
for PCR, and the application of these criteria to a ddPCR-based EGFR mutation test. To establish our criteria, 
we collected and analyzed 316 NSCLC FFPET-DNA samples of various ages and qualities from three sites. In 
addition, we compared the performance of the GenesWell ddEGFR mutation test (ddEGFR test) with that of the 
cobas EGFR mutation test (cobas EGFR test) in a retrospective clinical study using 171 NSCLC FFPET samples. 
Collectively, our results indicate that the use of sample criteria is critical for validating performance in clinical 
studies.
Results
Validation of internal quality control (iQC) in the ddEGFR test. Because the ddPCR-based test can 
lead to false positive results due to its intrinsic high sensitivity and FFPET characteristics, the cut-offs of the ddE-
GFR test were determined based on false-positive analyses using normal FFPET. Mutation calls were identified 
based on true-positive mutation values higher than limit of blank (LoB) and limit of detection (LoD) mutation 
index (MI) (1), which were established from analytical performance studies (Table 1). MI is a numerical value 
representing the ratio of mutant to internal quality control (iQC) copies, calculated as follows:
= ×
Mutant copies
iQC copies
Mutation index (%) 100
(1)
In the ddEGFR test, iQC copies can be converted to concentration of input DNA using an FFPE reference 
standard, suggesting that iQC index (2) is a representative index of amplifiable DNA. Because iQC copies were 
analyzed using 3.3 ng (1,000 genomic equivalents [GE]) of input DNA per reaction well, iQC index was calculated 
as follows:
=
iQC copies
Input DNA copies
iQC index
(2)
Using 40 wild-type FFPET samples, false-positive rates were determined for mutant calling of eight targets. 
The maximum number of copies was 5.4 per reaction, and the false-positive rates were below 0.5% of MI (Fig. 1). 
Exon Mutations detected Mutation report call LoB copies/MI (%)* LoD MI (%)†
18 G719A, G719C, G719S G719X 5.6/0.22 0.77
19 30 deletions 19del 3.0/0.09 0.83
20 S768I S768I 1.5/0.05 0.83
T790M T790M 6.8/0.34 0.78
C797S§ C797S 1.6/0.03 0.75
5 Insertions E20Ins 1.6/0.06 0.62
21 L858R L858R 1.6/0.03 0.71
L861Q L861Q 1.4/0.05 0.74
Table 1. Limit of blank and limit of detection of the ddEGFR test for mutant calls. *LoB = mean blank + 1.645 
(SD blank)36. †LoD MI (%) = meanlow concentration sample + 1.645 (SDlow concentration sample). §Using plasmids containing 
the non-predominant mutation for analytical performance. LoB was calculated using 9.9 ng of normal FFPET-
DNA. LoD was measured at 6 points (3–0.1%) serially diluted using NSCLC FFPET-DNA (19del, L858R) and 
reference standard FFPET-DNA (the other mutations) with wild-type FFPE-DNA. LoD was determined by the 
lowest amount of DNA that gave an EGFR “Mutation Detected” rate of at least 95% for the target mutation.
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We evaluated iQC using a reference standard. An FFPET-DNA reference standard with EGFR mutations was 
blended with a fixed amount of wild-type gDNA (3.3 ng, 1,000GE) targeting a 1.5% mutation level. The expected 
iQC index and MI were calculated from the quantity of input DNA, which showed that the measured MI (%) and 
iQC index closely matched the predicted value (iQC index = 1, MI = 1.5%) (Fig. 2A). Moreover, iQC was also 
validated by serial dilution of four concentrations of reference standard FFPET-DNA, which revealed that the 
Figure 1. Determination of a suitable cut-off based on false-positive analysis using normal FFPE blocks. 
Forty normal FFPE specimens were tested, and eight targets were evaluated for each specimen. The maximum 
number of copies was 5.4 per reaction (black dotted line) and the false-positive rate was below 0.5%.
Figure 2. Validation of internal quality control of the ddEGFR test. (A) Internal quality control (iQC) 
validation using reference standard. Each FFPE reference standard DNA extract for the EGFR mutations was 
blended with a fixed amount of wild-type gDNA (3.3 ng, 1,000GE) targeting a 1.5% mutation level, which was 
validated for use in the ddEGFR test. Values are expressed as the mean ± SD of nine experiments. (B) Internal 
quality control (iQC) validation using the reference standard. Four serial dilutions of each FFPE reference 
standard DNA extract were prepared and subjected to the ddEGFR test. Error bars indicate SD. Values are 
expressed as the mean ± SD of three experiments.
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measured values closely matched the expected values (Fig. 2B) and suggesting that the iQC copies represented 
the amount of input DNA.
Comparison of ddEGFR and cobas EGFR tests without sample criteria. The EGFR mutations 
in 316 NSCLC FFPET samples were analyzed using the ddEGFR and cobas EGFR tests. The study design is 
depicted in Fig. 3A. Both methods yielded valid results for all but one of the samples. Surprisingly, the ddE-
GFR and cobas EGFR tests were low concordant (positive percent agreement (PPA) = 94.04%, negative percent 
agreement (NPA) = 63.41%, overall percent agreement (OPA) = 78.10%, kappa coefficient value (κ) = 0.6650) 
(see Supplementary Table S2). The cobas EGFR test also exhibited very low concordance with the results of 
Sanger sequencing (Sanger) of 299 samples (PPA = 59.30%, NPA = 75.00%, OPA = 65.63%, κ = 0.4526) (see 
Supplementary Table S3).
Proof-of-concept for determination of minimum DNA quality suitable for PCR using the ddPCR 
method. To increase the concordance between the ddEGFR and cobas EGFR tests, we investigated the min-
imum DNA quality suitable for PCR analysis by re-analyzing the ddEGFR data, which provided iQC copies and 
index (Fig. 2A,B). FFPET block storage duration was reflected in the amount of amplifiable DNA, decreasing 
below 50% (mean of iQC index = 0.31, standard deviation, SD = 0.57) of 1,000 GE in 7–11-year-old samples. By 
contrast, in 2–6-year-old samples, the amount of amplifiable DNA was around 100% (mean of iQC index = 1.07, 
SD = 0.69) (Fig. 4A). Therefore, iQC index decreased with storage duration when FFPET was stored at room 
temperature. The pattern of DIN values from 315 FFPET-DNA samples measured in parallel was similar to those 
of iQC copies and index (Fig. 4B).
Establishment of iQC index for ddEGFR test using FFPET samples. We classified all 316 samples 
into four groups according to their storage durations, DIN values, and iQC copies, as illustrated in Fig. 1A. First, 
we analyzed DIN values for 57 discordant samples from among 169 samples derived from blocks stored for more 
than 6 years. The DIN value was less than 2.5 for most of the discordant samples (Fig. 4C). Among 147 samples 
with a block storage duration ≤ 6 years, 26 samples did not satisfy our DIN criteria, and were included in Group 1. 
To establish iQC index criteria, the 60 discordant samples in Group 1 were re-analyzed, and almost all (58/60) had 
an iQC index < 0.5 (Fig. 4D). Based on this result, the sample criteria were established as follows: block storage 
duration ≤ 6 years, DIN > 2.5, and iQC index ≥ 0.5. In addition, we observed a strong correlation between ddE-
GFR iQC index and DIN value, further supporting the idea that iQC index represents the quality of FFPET-DNA 
(p < 0.0001, see Supplementary Table S4).
Comparison of ddEGFR and cobas EGFR tests with or without iQC index criteria. When the iQC 
index cut-off was applied to 121 samples (block storage duration ≤ 6 years, DIN > 2.5), 113 samples remained 
(Fig. 3A, Group 2). Group 2 samples had a very high concordance rate between the ddEGFR and cobas EGFR 
tests (PPA = 100.00%, NPA = 76.00%, OPA = 94.69%, κ = 0.9197) (Table 2, see Supplementary Table S5).
Figure 3. Study design and specimen selection (work flow). (A) Patient sample dispositions for the applied 
sample criteria. For the pre-clinical study group, a total of 316 FFPE specimens were subjected to post-hoc 
analysis. (B) Patient sample dispositions for the applied iQC index. For the retrospective comparison study 
group, a total of 228 FFPE specimens were analyzed (D/O, Drop Out).
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Figure 4. Establishment of sample criteria. (A,B) Distributions of the ddEGFR iQC index (A) and DIN value 
(B) corresponding to sample storage time. The black line indicates the median value (*Genomic Equivalent; 
***p < 0.0001). (C,D) Establishment of sample criteria using discordant samples. Discordant samples were 
analyzed by comparing the results of the Cobas EGFR and ddEGFR tests. Plots show distributions of the 
correlation between DIN value (C), iQC index (D) and sample storage time of discordant samples. The black 
line represents the median value. The DIN values and iQC index of discordant samples are distributed under the 
red dotted line.
Pre-clinical study group
cobas EGFR Test
Group 2 Group 3
n = 113 MD MND Total n = 150 MD MND Total
ddEGFR Test
MD 88 6 94 MD 106 11* 117
MND 0 19 19 MND 0 33 33
Total 88 25 113 Total 106 44 150
PPA (95% C.I.) 100.0% (95.89–100.0%) 100.0% (96.58–100.0%)
NPA (95% C.I.) 76.00% (54.87–90.64%) 75.00% (59.66–86.81%)
OPA (95% C.I.) 94.69% (88.80–98.03%) 92.67% (87.26–96.28%)
PPV (95% C.I.) 93.62% (86.62–97.62%) 90.60% (83.80–95.21%)
NPV (95% C.I.) 100.0% (82.35–100.0%) 100.0% (87.26–100.0%)
Table 2. Comparison of ddEGFR and cobas EGFR results from FFPE samples eliminated by the sample criteria. 
*3 samples: cobas EGFR, 19del; ddEGFR, 19del/T790M. MD, mutation detected; MND, mutation not detected. 
Analysis of concordance rates between ddEGFR and cobas EGFR tests when the sample criteria were applied 
(Group 2 and Group 3). PPA, NPA, and OPA between the ddEGFR and cobas EGFR tests for the detection of 
EGFR mutations were 100%, 76.00%, and 94.69% (Group 2, left panel) and 100%, 75%, and 92.67% (Group 3, 
right panel), respectively.
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To determine the clinical implications of the iQC index, we applied this criterion to 316 FFPETs, resulting in 
the classification of 150 samples into Group 3 (Fig. 3A), and re-analyzed the concordance rate between the ddE-
GFR and cobas EGFR results. Group 3 samples had a very high concordance rate (PPA = 100.00%, NPA = 75.00%, 
OPA = 92.67%, κ = 0.8923) (Table 2, see Supplementary Table S6), similar to the results from Group 2 (applying 
all criteria). By contrast, Group 4 samples, in which the iQC index criterion was not satisfied, exhibited a very 
low concordance rate (PPA = 78.57%, NPA = 58.20%, OPA = 63.41%, κ = 0.3862) (see Supplementary Table S7). 
Therefore, we suggested that iQC index is a key factor in determining whether DNA is of sufficient quality for the 
ddEGFR test.
Analysis of discordant samples in a pre-clinical study. Applying the iQC index criterion, we 
re-analyzed the remaining 11 discordant samples in Group 3. A schematic representation of the re-analysis 
workflow for discordant samples is depicted in Supplementary Figure S1. In three of the samples, the ddEGFR 
test reported a double mutation (19del/T790M), whereas the cobas EGFR test and Sanger reported only a sin-
gle mutation (19del) (Table 2, Group 3). This may be a result of the low detection sensitivity of Sanger (~15%)23 
and cobas EGFR tests (LoD of T790M = ~3%; cobas EGFR v2). Based on the ddEGFR test results of these three 
samples, the MI of T790M was ~1% (1.11%, 1.16%, and 1.03%). Additionally, eight discordant samples were 
verified by Sanger, and no mutations were found (Table 3). Moreover, to observe the effect of tumor ratio, we 
performed macrodissection to enrich for tumor tissue, and then re-analyzed EGFR mutations in eight samples 
for which the cobas EGFR test had yielded negative results but the ddEGFR test yielded positive results. After 
macrodissection, the cobas EGFR test gave the same results as the ddEGFR test for four of the eight samples 
(Table 3). Thus, our results indicate that the ddEGFR test is more sensitive for EGFR mutation detection, 
independent of tumor ratio. Unusually, one discordant case was a mutation detected (T790M/G719X) in pre-
liminary analysis that was judged invalid by the ddEGFR test after macrodissection. Because the iQC index 
was very low (0.37, data not shown), it is possible that DNA degradation progress during the macrodissection 
process.
Retrospective comparative clinical study of EGFR tests. Next, we analyzed the EGFR mutation 
status of 228 samples using the ddEGFR and cobas EGFR tests; 57 samples were excluded based on the iQC 
index. The study design is depicted in Fig. 3B. The remaining 171 samples with iQC index ≥ 0.5 gave PPA of 
98.23%, NPA of 82.76%, and OPA of 92.98% between the ddEGFR and cobas EGFR tests (κ = 0.9029, Table 4, 
see Supplementary Table S8). Among 12 discordant samples, six were reported to have a double mutation 
according to the ddEGFR test but only a single mutation according to the cobas EGFR test. As expected, the 
MI of the additional detected mutation was very low. One discordant case was a mutation not detected by 
the cobas EGFR test, but detected (L861Q) by both ddEGFR test and Sanger. Conversely, another discordant 
case was a mutation not detected by the ddEGFR test but detected (19del) by the cobas EGFR test and Sanger 
(see Supplementary Table S9). This was a rare mutation of the 19del subtype (c.2239_2264del_insGCGAA) 
caused by a non-specific reaction that is not designed in the cobas EGFR test, and thus it cannot be employed 
to discriminate the possibility potential erroneous detection24 and beneficial cross-reaction of commercial 
diagnostic kits.
In addition, we measured DIN values from 228 FFPET-DNA samples and observed a pattern similar to that 
of iQC index. Furthermore, the majority of the most recent samples (within 1 year) had DIN > 2.5 and iQC 
index ≥ 0.5 (see Supplementary Fig. S2). These data revealed that iQC index is a very powerful indicator of the 
quality of FFPET-DNA. In addition, these observations demonstrate that the ddEGFR test is a robust diagnostic 
tool for the accurate detection of EGFR mutations in clinical practice.
Sample 
No
Block 
Storage 
age
C/N 
Ratio 
(%) DIN
Preliminary result After Macrodissection
cobas EGFR ddEGFR ddEGFR MI (%) Sanger cobas EGFR ddEGFR ddEGFR MI (%)
1 11 23 3.2 MND — MD L858R 0.8 WT N/A N/A N/A N/A —
2 11 51 2.2 MND — MD T790M/G719X 1.08/1.02 Invalid MND — Invalid — —
3 6 41 4.6 MND — MD L858R 1.57 WT MD L858R MD L858R 2.57
4 6 28 3.7 MND — MD G719X 10.17 WT MD G719X MD G719X 20.17
5 6 12 3.9 MND — MD L858R 5.91 WT MD L858R MD L858R 4.55
6 6 15 3.1 MND — MD L858R 7.4 WT N/A N/A N/A N/A —
7 3 43 4.4 MND — MD 20Ins 12.88 WT MND — MD E20Ins 7.4
8 3 34 4.1 MND — MD 19del 15.72 WT MD 19del MD 19del 3.15
Table 3. Re-analysis of eight of eleven discordant samples (in Group 3). MD, mutation detected; MND, 
mutation not detected; N/A, FFPE blocks not available. Eight of eleven discordant samples were verified by 
Sanger sequencing. In addition, after increasing the tumor-to-normal tissue ratio, detection of EGFR mutations 
was re-analyzed using the cobas EGFR and ddEGFR tests. After enrichment of tumor tissue, the cobas EGFR 
test could identify previously undetected EGFR mutations in four out of the eight samples. However, the 
ddEGFR analysis yielded data identical to the preliminary results.
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Discussion
The quality of FFPET-DNA has been largely ignored in the clinical research and diagnosis field, and the internal 
controls of most commercial diagnostic kits have been used only to validate assays. Changes in mutation status 
due to the low quality of FFPET-DNA may result in incorrect diagnoses. Therefore, considerable effort is required 
to optimize the sample criteria for determining the quality of FFPET-DNA that is suitable for PCR. In this study, 
we established iQC index criteria to determine the minimum quality of FFPET-DNA and demonstrated the ben-
efits of implementing these criteria benefits in a real-world clinical application.
In our experiments, we found that both automated tissue preparation system (TPS; Siemens Healthcare, 
Erlangen, Germany), which can minimize handling errors and decrease the effect of formaldehyde-induced 
DNA–DNA and DNA–protein crosslinks6,9, and uracil-DNA glycosylase (UDG) treatment are powerful strat-
egies for reducing false positives caused by sequence artifacts10,25–27. However, sequence artifacts due to DNA 
fragmentation remained a problem. Depending on the degree of fragmentation, the same quantities of DNA from 
different FFPET samples can contain widely different amounts of amplifiable DNA templates28. For this reason, 
PCR-based methods such as qPCR, ddPCR, and next-generation sequencing (NGS) are preferable for quantifying 
the amount of amplifiable template in FFPET-DNA19.
We showed that iQC copies can be used to as an indicator of the concentration of input DNA (Fig. 2A,B) and 
that a novel concept for mutation calling termed MI can be used as an indicator of the mutation level, which in 
turn reflects DNA quality. MI provides a much more accurate indication of the mutation level than mutation 
frequency, which is simply calculated based on input DNA concentration. Accordingly, we designed an iQC that 
measures the amount of EGFR exon 20 to assess the amount of amplifiable FFPET-DNA. Because elevated EGFR 
expression has been observed in NSCLC23, the internal control should be designed to represent the EGFR gene 
copy number.
Interestingly, some discordant samples reported as single mutations by the cobas EGFR test were shown to 
have double mutation by the ddEGFR test in pre-clinical (Table 2) and clinical studies (Table 4). The additional 
detected MI was around 1%, as expected. According to a clonal selection model, EGFR-TKI treatment may lead 
to the selection of T790M mutant cells, and thus even a small fraction of T790M positive tumor cells at the begin-
ning of treatment could lead to clinical EGFR-TKI resistance16. Therefore, is very important to detect even a small 
fraction of mutations.
The discordant results were largely due to the difference in LoD between both tests. Specifically, some muta-
tions detected by the ddEGFR test cannot be detected by the cobas EGFR test because the sensitivity of the 
ddEGFR test is higher. In the pre-clinical study Group 3, L858R MIs were relatively low in cobas EGFR-negative 
samples (around 5%, Table 3). Considering that the LoD of the cobas EGFR test was 5%, these MI values, which 
reflect sample quality and mutation level, are reasonable. When the iQC index was applied, the proportion of such 
discordant samples was small.
The cobas EGFR test recommends macrodissection of low-percent tumor tissues (below 10%) to improve 
detectability29. When the cobas EGFR test yielded a result of ‘mutation not detected’ (MND), even though the 
C/N ratio was over 10%, the EGFR mutation was re-analyzed after increasing the tumor ratio by macrodissection. 
The cobas EGFR test yielded the same results as the ddEGFR test for four of the eight samples (Table 3), showing 
that ddEGFR exhibits superior analytical performance. Thus, the detectability of the cobas EGFR test may be 
increased by enriching for tumor tissue, e.g., by macrodissection, but this manipulation requires extra time and 
effort. By contrast, the ddEGFR test does not require macrodissection and improves reliability.
For 1-year-old samples (n = 46) in the clinical study group, all iQC index and DIN values satisfied the sample 
criteria (iQC index ≥ 0.5, DIN > 2.5) (see Supplementary Fig. S2), suggesting that the low age samples used in 
clinical practice will have minimal problems with DNA quality. Previous studies have reported that cobas EGFR 
test and Sanger sequencing results are highly concordant when used on low age samples30–32. By contrast, the 
concordance rate between cobas EGFR test and Sanger sequencing of pre-clinical study samples was very low 
(see Supplementary Table S3), but was improved when the iQC index was applied (Data not shown). Given the 
Retrospective comparison study, Applied iQC index (n = 171)
cobas EGFR Test
MD MND Total
ddEGFR Test
MD 111 10* 121
MND 2 48 50
Total 113 58 171
PPA (95% C.I.) 98.23% (93.75–99.78%)
NPA (95% C.I.) 82.76% (70.57–91.41%)
OPA (95% C.I.) 92.98% (88.06–96.32%)
PPV (95% C.I.) 91.74% (85.33–95.97%)
NPV (95% C.I.) 96.00% (86.29–99.51%)
Table 4. Retrospective comparative study. MD, mutation detected; MND, mutation not detected. *3 samples: 
cobas EGFR, 19del; ddEGFR, 19del/T790M. 1 sample: cobas EGFR, G719X; ddEGFR, G719X/L861Q. 1 sample: 
cobas EGFR, L858R; ddEGFR, G719X/L858R. 1 sample: cobas EGFR, L858R; ddEGFR, T790M/L858R. Method 
correlation between ddEGFR and cobas EGFR test. Samples with valid ddEGFR and cobas EGFR test results 
were included in the agreement analysis. PPA, NPA, and OPA between the ddEGFR and cobas EGFR tests for 
the detection of EGFR mutations were 98.23%, 82.76%, and 92.98%, respectively.
www.nature.com/scientificreports/
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additional cost and effort required for DIN measurement, the iQC index is a robust indicator of the minimum 
DNA quality required for PCR amplification, as it takes into account the various types of DNA damage caused by 
FFPET processing and long-term storage.
In addition, iQC index ≥ 0.5 is an indicator that guarantees clinical equivalence obtained through compar-
ative clinical studies with existing approved diagnostics test (cobas EGFR test). Clinical equivalence cannot be 
guaranteed for samples with an iQC index < 0.5. However, discordance of samples with iQC index < 0.5 can be 
explained by two causes. The first cause may be due to the possibility of false negative results of cobas EGFR test. 
Second, there is a possibility of false positive result due to ultra-sensitivity of ddEGFR test. The analytical perfor-
mance of the ddEGFR test indicates a high possibility of false negative results on the cobas EGFR test. However, 
it is questionable whether mutations detected in samples with an iQC index < 0.5 (especially mutations detected 
at low MI %) are related to drug treatment response. This must be verified through prospective clinical trials. 
Small-scale independent retrospective clinical studies for the ddEGFR test have shown responses of patients 
treated with an EGFR-TKI, even of patients with an iQC index < 0.5 (unpublished). Therefore, an iQC index ≥ 0.5 
is a numerical value used in comparative clinical studies to guarantee clinical equivalence between the results of 
the ddEGFR and cobas EGFR tests. This means that iQC index may be changed through an independent prospec-
tive clinical trial for ddEGFR test. Also, using another approved kit for comparative clinical study, the iQC index 
may be changed for clinical equivalence. This is the result of considering clinical cut-off not only to compare the 
mutation results but also to ensure EGFR-TKI response.
We also observed that the iQC index could be used to obtain a diagnosis using other cancer type samples 
(colorectal cancer) and other diagnostic kits, including the ddPCR-based KRAS mutation test and the cobas 
KRAS mutation test. Similar to the results of this study, we observed that when the iQC index was applied, the 
concordance rate between the results of the two kits increased significantly (data not shown). Overall, the iQC 
index could be a useful criterion for judging the quality of FFPET-DNA.
In particular, the iQC index seems to be more useful in diagnoses using liquid biopsy samples (e.g. cell free 
tumor DNA, ctDNA). The iQC index may be necessary for liquid biopsy specimens since the quality of ctDNA 
can vary diversely by frequent fragmentation, which is a biological property of ctDNA, variations in sample col-
lection and storage by each hospitals, and by logistic issues.
In conclusion, detection of genetic mutations in FFPET samples is difficult due to DNA fragmentation dur-
ing the storage period and sequence artifacts arising from DNA damage. The iQC index allowed selection of 
appropriate FFPET-DNA samples for companion diagnosis using a ddPCR-based mutation test. Furthermore, we 
suggest that clinical trials using FFPE should present criteria reflecting the quality of the DNA. Our ddPCR-based 
EGFR mutation test exhibited superior analytical performance to the cobas EGFR test. A future clinical study 
should evaluate the use of the ddPCR-based EGFR test to determine the suitability of NSCLC patients for 
EGFR-TKI treatment in cases in which the cobas EGFR test reports no mutation.
Materials and Methods
Study design. To establish sample criteria, a total of 316 samples obtained from NSCLC patients were tested 
for EGFR mutations. A post-hoc analysis of these pre-clinical data was conducted for both the ddEGFR and cobas 
EGFR test results. Based on the established sample criteria, an independent retrospective comparison study was 
performed to estimate the concordance between the ddEGFR and cobas EGFR tests; for this purpose, 228 FFPET-
DNA samples from NSCLC patients were analyzed by both tests. Both EGFR mutation tests were performed in 
a double-blind fashion by an independent laboratory (Abion Inc., Seoul, Korea). The study design (workflow) is 
depicted in Fig. 3.
The major study objectives were 1) to establish sample criteria to determine the minimum FFPET-DNA qual-
ity suitable for PCR, and 2) to compare the clinical performances of the ddEGFR and cobas EGFR tests.
FFPET collection and DNA extraction, and determination of DNA quantity and quality. FFPET 
blocks of resected or biopsy samples from NSCLC patients (n = 316) collected from 2005 to 2014 were retrieved 
from the Department of Pathology, Samsung Medical Center (n = 200) (SMC; Seoul, Korea), Asan Medical 
Center (n = 66) (AMC; Seoul, Korea), and Severance Hospital (n = 50) (Seoul, Korea). This study was approved 
by the Institutional Review Board (IRB) of SMC and Seoul National University (study ID: SMC-2014-05-084-
002). For the retrospective comparison study, 228 archived FFPET blocks from NSCLC patients collected 
between 2010 and 2016 were obtained from Department of Pathology, SMC. This study was approved by the 
IRB of SMC and the Ministry of Food and Drug Safety (MFDS) of Korea (study ID: SMC-2016-07-104-002). 
Patient information was anonymized and de-identified prior to analysis. From each FFPET, 10 μm sections were 
cut and subjected to DNA extraction. H&E-stained sections containing tumor lesions marked by a patholo-
gist (S.W.C.) were scanned, and the cancer/normal (C/N) ratio was calculated using the Pannoramic Viewer 
Software v.1.15.4 (3DHISTECH, Budapest, Hungary). DNA extraction from FFPETs was performed using an 
automated Tissue Preparation System (TPS; Siemens Healthcare, Erlangen, Germany) with VERSANT® Tissue 
Preparation Reagents, as described previously33. Total nucleic acids were eluted with 100 μL elution buffer con-
taining UDG provided by the manufacturer. For all samples, DNA concentration was assessed using the Qubit™ 
3.0 Fluorometer (ThermoFisher Scientific, MA, USA). The DNA integrity number (DIN), reflecting the DNA 
fragmentation level34 of genomic DNA (gDNA), was analyzed on a 2200 TapeStation system with Genomic DNA 
Screen Tape (Agilent Technologies, CA, USA).
Validation of internal quality control (iQC) of ddEGFR test. The ddEGFR test (Gencurix Inc., 
Seoul, Korea) was designed as a highly sensitive ddPCR-based diagnostic test for detecting 45 mutation sites 
within the exon 18–21 region of the EGFR gene using four reactions. The amplified fragments, which contain 
the fluorophores FAM™ or HEX™, are displayed as dots (droplets) and can be used to calculate concentrations 
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(copies/20 μL) based on the Poisson distribution35. The details of the specific mutations detected by the assay are 
provided in Table 1 and Supplementary Table S1. The non-clinical performance studies followed the guidelines 
approved by the Clinical and Laboratory Standards Institute (CLSI) and the Korea-MFDS. For validation of inter-
nal quality control of ddEGFR test, FFPE reference standard DNA extracts (HDx™ Reference Standard, Horizon 
Discovery, Cambridge, UK) whit EGFR mutations were blended with a fixed amounts of wild-type gDNA (3.3 
ng, 1,000 GE; Promega, Fitchburg, WI, USA) and each sample, with a target MI of 1.5%. In addition, four serial 
dilutions of each sample (9.9 ng, 6.6 ng, 3.3 ng, and 1.65 ng) were prepared and analyzed using the ddEGFR test. 
The iQC copies and target MI of each sample was confirmed based on the input DNA concentration and target 
MI (1.5%).
Biomarker analysis. The ddEGFR test was performed in a 20 μL volume containing 3.3 ng (1,000 GE)/reac-
tion of template DNA on a Droplet Digital™ PCR (ddPCR) system (Bio-Rad, Hercules, CA, USA). The ddPCR 
assay was conducted as described previously33. Thresholds for detection were set manually based on results from 
non-template control wells and negative control wells containing wild-type gDNA (Promega). PCR amplifica-
tion for the cobas EGFR test (Roche Molecular Systems Inc., Branchburg, NJ, USA) was performed on a cobas 
z 480 Analyzer. The cobas EGFR test requires 150 ng total input DNA. Both mutation tests were analyzed in a 
double-blind fashion, and the results were matched after analysis.
For mutation screening of EGFR exons 18, 19, 20, and 21 by 2× bidirectional Sanger sequencing, regions 
of interest were amplified by PCR, and the amplified samples were processed at an independent laboratory 
(Macrogen, Seoul, Korea) using a validated protocol. Sanger sequencing results were cross-checked and inter-
preted by a pathologist (Y.L.C.).
Methods correlation and statistical analysis. Agreement analysis for all methods was based on muta-
tion report calls (Table 1). Statistical analysis was performed using GraphPad Prism™ (GraphPad Software Inc., 
San Diego, USA) and the R 1.6.12 package ‘psych’ (http://CRAN.R-project.org/package=psych). For the agree-
ment analyses, positive percent agreement (PPA), negative percent agreement (NPA), and overall percent agree-
ment (OPA) were calculated with their corresponding 95% confidence intervals (CIs).
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